Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL.
Group IIA secretory phospholipase A2 is an acute phase enzyme, co-expressed with serum amyloid A protein. Both are present in atherosclerotic lesions. We report that human normal and acute phase high density lipoproteins and low density lipoprotein are effective substrates for human group IIA phospholipase A2. The enzyme hydrolyzed choline and ethanolamine glycerophospholipids at the sn -2 position resulting in an accumulation of the corresponding lysophospholipids, including the unhydrolyzed alkyl and alkenyl ether derivatives. The hydrolysis of acute phase high density lipoprotein was 2- to 3-fold more rapid and intensive than of normal high density lipoprotein. The hydrolysis of lipoproteins was noted at enzyme concentration as low as 0.05 microgram/mg protein, which was within the range observed in the circulation in acute and chronic inflammatory diseases. The enzyme hydrolyzed the different molecular species of the residual glycerophospholipids in proportion to their mass, showing no preference for the release of arachidonic acid. Group IIA phospholipase A2 preferentially attacked the hydroxy and hydroperoxy linoleates and possibly other oxygenated fatty acids, which were released from the glycerophospholipids at early times of incubation. There was no effect on the content or molecular species composition of the sphingomyelins or neutral lipids of the lipoproteins. In conclusion, human plasma lipoproteins are the first reported natural biological substrates for human group IIA phospholipase A2. The enhanced hydrolysis of acute phase high density lipoproteins is probably due to its association with serum amyloid A protein, which enhances the activity of the enzyme and may promote its penetration to the lipid monolayer. As sPLA2-induced hydrolysis of the lipoproteins leads to accumulation of lysophosphatidylcholine and potentially toxic oxygenated fatty acids, overexpression of this enzyme may be proatherogenic.
Pruzanski
W
W
Inflammation Research Group, The Wellesley Central Hospital Research Institute, University of Toronto, Toronto, Ontario, Canada.
Stefanski
E
E
de Beer
F C
FC
de Beer
M C
MC
Vadas
P
P
Ravandi
A
A
Kuksis
A
A
D000210:Acute-Phase Reaction / Q000097:blood*; D000447:Aldehydes / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D054501:Group II Phospholipases A2; D006801:Humans; D006868:Hydrolysis; D008054:Lipid Peroxides / Q000378:metabolism; D008075:Lipoproteins, HDL / Q000097:blood*; D013058:Mass Spectrometry; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D010743:Phospholipids / Q000378:metabolism; D014461:Ultracentrifugation
D000447:Aldehydes; D005230:Fatty Acids, Nonesterified; D008054:Lipid Peroxides; D008075:Lipoproteins, HDL; D010743:Phospholipids; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2